



World Health  
Organization

CONSOLIDATED HIV STRATEGIC  
INFORMATION GUIDELINES

# DRIVING IMPACT THROUGH PROGRAMME MONITORING AND MANAGEMENT

WEB ANNEX B  
INDICATOR ALIGNMENT ACROSS GLOBAL  
MONITORING AND EVALUATION FRAMEWORKS

APRIL 2020

The text of the Consolidated strategic information guidelines, April 2020, is available online at: <https://apps.who.int/iris/bitstream/handle/10665/331697/9789240000735-eng.pdf>

## Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Web Annex B. Indicator alignment across global monitoring and evaluation frameworks

ISBN 978-92-4-000437-5 (electronic version)

© World Health Organization 2020

**Some rights reserved.** This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; <https://creativecommons.org/licenses/by-nc-sa/3.0/igo>).

Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: "This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition".

Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization.

**Suggested citation.** Web Annex B. Indicator alignment across global monitoring and evaluation frameworks. In: Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management. Geneva: World Health Organization; 2020. Licence: **CC BY-NC-SA 3.0 IGO**.

**Cataloguing-in-Publication (CIP) data.** CIP data are available at <http://apps.who.int/iris>.

**Sales, rights and licensing.** To purchase WHO publications, see <http://apps.who.int/bookorders>. To submit requests for commercial use and queries on rights and licensing, see <http://www.who.int/about/licensing>.

**Third-party materials.** If you wish to reuse material from this work that is attributed to a third party, such as tables, figures or images, it is your responsibility to determine whether permission is needed for that reuse and to obtain permission from the copyright holder. The risk of claims resulting from infringement of any third-party-owned component in the work rests solely with the user.

**General disclaimers.** The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement.

The mention of specific companies or of certain manufacturers' products does not imply that they are endorsed or recommended by WHO in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.

All reasonable precautions have been taken by WHO to verify the information contained in this publication. However, the published material is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the material lies with the reader. In no event shall WHO be liable for damages arising from its use.

This publication forms part of the WHO guideline entitled *Consolidated HIV strategic information guidelines: driving impact through programme monitoring and management*. It is being made publicly available for transparency purposes and information, in accordance with the *WHO handbook for guideline development*, 2nd edition (2014).

# WEB ANNEX B INDICATOR ALIGNMENT ACROSS GLOBAL MONITORING AND EVALUATION FRAMEWORKS

		Alignment with (C = consistent with, S = similar to, R = related)		
Ref. no.	Short name	GAM	GF	MER
PR.1	Condom use (KP & Gen pop)	S	C	
PR.2	Condoms distributed	C		
PR.3	PrEP uptake	C	C	S
PR.4	PrEP continuation (at 3 months)			
PR.5	Currently on PrEP	C		C
TL.1	PLHIV who know their HIV status	C	C	
TL.2	HTS testing volume and positivity	S	S	S
TL.3	Linkage to ART		C	
TL.4	HTS index testing and partner notification			C
TL.5	HTS self-testing			
TL.6	Know their status (KP)	C	S	
AV.1	PLHIV on ART	C	C	C
AV.2	Total attrition from ART		C	S
AV.3	PLHIV who have suppressed VL	S	S	S
AV.4	New ART patients	R	R	S
AV.5	Late ART initiation			
AV.6	VL testing coverage			R
AV.7	Early VL testing (at 6 months)			
AV.8	Appropriate second VL test			
AV.9	ARV toxicity prevalence			
TB.1	TPT initiation	S	S	
TB.2	TPT completion			S
TB.3	TB diagnostic testing type			
TB.4	PLHIV with active TB disease	C		
VT.1	Viral suppression at labour and delivery			
VT.2	EID coverage	C	C	C
VT.3	Infant ARV prophylaxis coverage			
VT.4	ART coverage in pregnant women	C	C	S
VT.5	ART coverage in breastfeeding mothers			
VT.6	Final outcome of PMTCT			C
ST.1	Syphilis screening coverage (in ANC)		C	

Ref. no.	Short name	Alignment with (C = consistent with, S = similar to, R = related)		
		GAM	GF	MER
ST.2	Syphilis treatment coverage (in ANC)			
ST.3	Cervical cancer screening among women living with HIV	S		S
SD.1	Avoidance of health care due to stigma and discrimination (KP)	C	C	
SD.2	Avoidance of health care due to stigma and discrimination (PLHIV)			
KP.1	Coverage of HIV prevention (KP)	S	S	S
KP.2	Needles and syringes distributed	C	C	
KP.3	Coverage of OST	C	R	R
KP.4	Safe injecting practices (PWID)	C	C	
GW.1	AGYW HIV/SRH integration			
DfC.1	VMMC scale-up	C	C	C
DfC.2	VMMC adverse events			
DfI.1	Facility-level injection safety			
DfI.2	Rate of unsafe injections per person			
DfB.1	Facility-level blood safety			
DfB.2	Quality-assured blood testing			
DfT.1	TB screening coverage among new ART patients		S	R
DfT.2	TB symptom screened positive among new ART patients			R
DfT.3	TB testing among symptom screened positive			
DfT.4	TB diagnosis among those tested for TB			
DfT.5	TB treatment initiation among diagnosed			
DfH.1	HCV screening coverage	C		
DfH.2	HCV treatment coverage			
BI.1	People living with HIV		C	
BI.2	HIV prevalence among KP (per 1000 population)	C	C	
BI.3	New HIV infections	C	C	
BI.4	Final MTCT rate	C	C	
BI.5	AIDS mortality	C	C	

### Alignment Categories:

Consistent (C): Numerator and denominator definitions are the same.

Similar (S): Basic definitions are the same, but there are some differences in how the numerator or denominator is calculated.

Related (R): An indicator is reflected as only a numerator or denominator or a disaggregation category in other frameworks.

Blank cells indicate there is no equivalent indicator included in that M&E framework.

### Partner Designations:

GAM = Global AIDS Monitoring indicators (v.2020)

GF = Global Fund for AIDS, TB, and Malaria Modular Framework indicators (v. October 2019)

MER = United States President's Emergency Fund for AIDS Relief, Monitoring, Evaluation and Reporting indicators (v.2.4 FY20).

**For more information, contact:**

World Health Organization  
Department of HIV/AIDS  
20, avenue Appia  
1211 Geneva 27  
Switzerland

Email: [hiv-aids@who.int](mailto:hiv-aids@who.int)

[www.who.int/hiv](http://www.who.int/hiv)

ISBN 978-92-4-000437-5

